Puma Biotechnology Announces Presentation of Phase II Study Results of Alisertib for Endocrine Resistant Metastatic Breast Cancer (Tbcrc 041)
Puma Biotechnology宣布介绍Alisertib治疗耐内分泌转移性乳腺癌的II期研究结果（Tbcrc 041）
Puma Biotechnology Announces Presentation of Phase II Study Results of Alisertib for Endocrine Resistant Metastatic Breast Cancer (Tbcrc 041)
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.